CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 92 enrolled
Drug / intervention
Byetta 5Mcg Pen Injectiondrug
Likely dose
Byetta 5Mcg Pen Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02157974
NCT02157974Phase 3Completed

Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls

University of Colorado, Denver·interventional·Posted Jun 6, 2014·Updated Jun 4, 2024

In Brief

A Phase 3 clinical trial evaluating Byetta 5Mcg Pen Injection for Hepatic Steatosis and 2 related conditions. Completed, enrolled 92 participants across 1 site.

Detailed Summary

Women with polycystic ovarian syndrome (PCOS) have increased rates of hepatic steatosis compared to weight similar women with regular menses. It is unclear if this is related to high testosterone or insulin resistance. The investigators will assess hepatic glucose release, rates of lipolysis and hepatic de novo lipogenesis in the fasted and postprandial state to determine if alterations in the processes contribute to hepatic steatosis. Participants will be overweight, sedentary girls with or without PCOS. Those with PCOS will either be medication naive, or must be taking metformin or combined oral contraceptives (COCPs) for a period of at least 6 months prior to study procedures.

Study Details

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 6, 2014
Enrollment StartAug 1, 2014
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 12.1 years ago

Interventions

Byetta 5Mcg Pen Injectiondrug

10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola